title: [Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
abstract: By combining the expertise of clinical neuroscience, the aim of neuro-oncology is to optimize diagnostic planning and therapy of primary brain tumors in an interdisciplinary setting together with radio-oncology and medical oncology. High-end imaging frequently allows brain tumors to be diagnosed preoperatively with respect to tumor entity and even tumor malignancy grade. Moreover, neuroimaging is indispensable for guidance of biopsy resection and monitoring of therapy. Surgical resection of intracranial lesions with preservation of neurological function has become dramatically more extensive. Tools to achieve this goal are, for example neuronavigation, functional magnetic resonance imaging (fMRI), tractography, intraoperative cortical stimulation and precise intraoperative definition of tumor margins by virtue of various techniques. In addition to classical histopathological diagnosis and tumor classification, modern neuropathology is supplemented by molecular characterization of brain tumors in order to provide clinicians with prognostic and predictive (of therapy) markers, such as codeletion of chromosomes 1p and 19q in anaplastic gliomas and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas. Although this is not yet individualized tumor therapy, the increasingly more detailed analysis of the molecular pathogenesis of an individual glioma will eventually lead to specific pharmacological blockade of disturbed intracellular pathways in individual patients. This article gives an overview of the state of the art of interdisciplinary neuro-oncology whereby part 1 deals with the diagnostics and surgical therapy of primary brain tumors and part 2 describes the medical therapy of primary brain tumors.
authors.affiliation: Interdisziplinäre Sektion für Neuroonkologie, Klinik für Neurochirurgie, Zentrum für Neurologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
authors.forename: G
authors.initials: G
authors.lastname: Tabatabai
authors.forename: E
authors.initials: E
authors.lastname: Hattingen
authors.forename: J
authors.initials: J
authors.lastname: Schlegel
authors.forename: W
authors.initials: W
authors.lastname: Stummer
authors.forename: U
authors.initials: U
authors.lastname: Schlegel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D057054:Molecular Imaging / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009462:Neurology / Q000379:methods; D010348:Patient Care Team
chemical_list: D000970:Antineoplastic Agents